{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:50:11Z","timestamp":1770972611785,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Region V\u00e4sterbotten in Ume\u00e5, Sweden","award":["RV 967602"],"award-info":[{"award-number":["RV 967602"]}]},{"name":"The Swedish Society of Medicine","award":["SLS-934237"],"award-info":[{"award-number":["SLS-934237"]}]},{"name":"Bengt Ihre Research Fellowship Grant"},{"DOI":"10.13039\/501100001725","name":"The Royal Swedish Academy of Sciences","doi-asserted-by":"crossref","award":["LM2021-0010"],"award-info":[{"award-number":["LM2021-0010"]}],"id":[{"id":"10.13039\/501100001725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001725","name":"The Royal Swedish Academy of Sciences","doi-asserted-by":"crossref","award":["LM2023-0012"],"award-info":[{"award-number":["LM2023-0012"]}],"id":[{"id":"10.13039\/501100001725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1245\/s10434-025-18426-y","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:11:33Z","timestamp":1762171893000},"page":"2620-2631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant Therapy for Invasive Intraductal Papillary Mucinous Neoplasms: A Comparative Study With Pancreatic Ductal Adenocarcinoma"],"prefix":"10.1245","volume":"33","author":[{"given":"Hiroyuki","family":"Ishida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Rodriguez Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oskar","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrii","family":"Khomiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole Baranda","family":"Balmaceda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetto","family":"Mungo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard D.","family":"Schulick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Del Chiaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"18426_CR1","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1056\/NEJMra2309041","volume":"391","author":"TA Gonda","year":"2024","unstructured":"Gonda TA, Cahen DL, Farrell JJ. Pancreatic cysts. N Engl J Med. 2024;391:832\u201343. https:\/\/doi.org\/10.1056\/NEJMra2309041.","journal-title":"N Engl J Med."},{"key":"18426_CR2","doi-asserted-by":"publisher","first-page":"12118","DOI":"10.3748\/wjg.v20.i34.12118","volume":"20","author":"M Del Chiaro","year":"2014","unstructured":"Del Chiaro M, Segersv\u00e4rd R, L\u00f6hr M, Verbeke C. Early detection and prevention of pancreatic cancer: is it really possible today? World J Gastroenterol. 2014;20:12118\u201331. https:\/\/doi.org\/10.3748\/wjg.v20.i34.12118.","journal-title":"World J Gastroenterol."},{"key":"18426_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/MPA.0b013e318215010c","volume":"40","author":"K Yamaguchi","year":"2011","unstructured":"Yamaguchi K, Kanemitsu S, Hatori T, et al. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas. 2011;40:571\u201380. https:\/\/doi.org\/10.1097\/MPA.0b013e318215010c.","journal-title":"Pancreas."},{"key":"18426_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijsu.2019.09.014","volume":"71","author":"L Aronsson","year":"2019","unstructured":"Aronsson L, Bengtsson A, Tor\u00e9n W, Andersson R, Ansari D. Intraductal papillary mucinous carcinoma versus pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Int J Surg. 2019;71:91\u20139. https:\/\/doi.org\/10.1016\/j.ijsu.2019.09.014.","journal-title":"Int J Surg."},{"key":"18426_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041185","author":"IA Ziogas","year":"2023","unstructured":"Ziogas IA, Rodriguez Franco S, Schmoke N, et al. Comparison of invasive pancreatic ductal adenocarcinoma versus intraductal papillary mucinous neoplasm: a National Cancer Database analysis. Cancers Basel. 2023. https:\/\/doi.org\/10.3390\/cancers15041185.","journal-title":"Cancers Basel."},{"key":"18426_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","volume":"20","author":"C Springfeld","year":"2023","unstructured":"Springfeld C, Ferrone CR, Katz MHG, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol. 2023;20:318\u201337. https:\/\/doi.org\/10.1038\/s41571-023-00746-1.","journal-title":"Nat Rev Clin Oncol."},{"key":"18426_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41575-023-00856-2","volume":"21","author":"TF Stoop","year":"2024","unstructured":"Stoop TF, Theijse RT, Seelen LWF, et al. Preoperative chemotherapy, radiotherapy, and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:101\u201324. https:\/\/doi.org\/10.1038\/s41575-023-00856-2.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"18426_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/SLA.0000000000005925","volume":"279","author":"T Sugawara","year":"2024","unstructured":"Sugawara T, Rodriguez Franco S, Sherman S, et al. Neoadjuvant chemotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: an updated nationwide study. Ann Surg. 2024;279:331\u20139. https:\/\/doi.org\/10.1097\/SLA.0000000000005925.","journal-title":"Ann Surg."},{"key":"18426_CR9","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1245\/s10434-023-14875-5","volume":"31","author":"A Fogliati","year":"2024","unstructured":"Fogliati A, Zironda A, Fiorentini G, et al. Outcomes of neoadjuvant chemotherapy for invasive intraductal papillary mucinous neoplasm compared with de novo pancreatic adenocarcinoma. Ann Surg Oncol. 2024;31:2632\u20139. https:\/\/doi.org\/10.1245\/s10434-023-14875-5.","journal-title":"Ann Surg Oncol."},{"key":"18426_CR10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/ags3.12790","volume":"8","author":"S Hirono","year":"2024","unstructured":"Hirono S, Higuchi R, Honda G, et al. Is multidisciplinary treatment effective for invasive intraductal papillary mucinous carcinoma? Ann Gastroenterol Surg. 2024;8:845\u201359. https:\/\/doi.org\/10.1002\/ags3.12790.","journal-title":"Ann Gastroenterol Surg."},{"key":"18426_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/SLA.0000000000003859","volume":"275","author":"A Oba","year":"2022","unstructured":"Oba A, Croce C, Hosokawa P, et al. Prognosis-based definition of resectability in pancreatic cancer: a road map to new guidelines. Ann Surg. 2022;275:175\u201381. https:\/\/doi.org\/10.1097\/SLA.0000000000003859.","journal-title":"Ann Surg."},{"key":"18426_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073995","volume":"383","author":"M Del Chiaro","year":"2023","unstructured":"Del Chiaro M, Sugawara T, Karam SD, Messersmith WA. Advances in the management of pancreatic cancer. BMJ. 2023;383:e073995. https:\/\/doi.org\/10.1136\/bmj-2022-073995.","journal-title":"BMJ."},{"key":"18426_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006687","author":"JR Habib","year":"2025","unstructured":"Habib JR, Rompen IF, Javed AA, et al. Neoadjuvant chemotherapy for intraductal papillary mucinous neoplasm-derived pancreatic cancer. Ann Surg. 2025. https:\/\/doi.org\/10.1097\/SLA.0000000000006687.","journal-title":"Ann Surg."},{"key":"18426_CR14","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008.","journal-title":"J Clin Epidemiol."},{"key":"18426_CR15","unstructured":"Lurie RH, Cardin DB, Gabriela Chiorean E, et al. NCCN Guidelines Version 3. 2024 Pancreatic Adenocarcinoma. Retrieved 5 September 5 at https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1455."},{"key":"18426_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, De Vries E, et al. RECIST 1.1\u2014update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081.","journal-title":"Eur J Cancer."},{"key":"18426_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg."},{"key":"18426_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant."},{"key":"18426_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jamcollsurg.2011.04.003","volume":"213","author":"JA Waters","year":"2011","unstructured":"Waters JA, Schnelldorfer T, Aguilar-Saavedra JR, et al. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American joint committee on cancer stage. J Am Coll Surg. 2011;213:275\u201383. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2011.04.003.","journal-title":"J Am Coll Surg."},{"key":"18426_CR20","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1136\/gut.2010.232272","volume":"60","author":"M Mino-Kenudson","year":"2011","unstructured":"Mino-Kenudson M, Fern\u00e1ndez-del Castillo C, Baba Y, et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut. 2011;60:1712\u201320. https:\/\/doi.org\/10.1136\/gut.2010.232272.","journal-title":"Gut."},{"key":"18426_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29803","author":"MT McMillan","year":"2016","unstructured":"McMillan MT, Lewis RS, Drebin JA, et al. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN). Cancer. 2016. https:\/\/doi.org\/10.1002\/cncr.29803.","journal-title":"Cancer."},{"key":"18426_CR22","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1111\/jgh.16686","volume":"39","author":"JR Habib","year":"2024","unstructured":"Habib JR, Rompen IF, Javed AA, et al. Outcomes in intraductal papillary mucinous neoplasm-derived pancreatic cancer differ from PanIN-derived pancreatic cancer. J Gastroenterol Hepatol. 2024;39:2360\u20136. https:\/\/doi.org\/10.1111\/jgh.16686.","journal-title":"J Gastroenterol Hepatol."},{"key":"18426_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000006272","author":"J Lucocq","year":"2024","unstructured":"Lucocq J, Halle-Smith J, Haugk B, et al. Long-term outcomes following resection of adenocarcinoma arising from intraductal papillary mucinous neoplasm (A-IPMN) versus pancreatic ductal adenocarcinoma (PDAC). Ann Surg. 2024. https:\/\/doi.org\/10.1097\/sla.0000000000006272.","journal-title":"Ann Surg."},{"key":"18426_CR24","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1245\/s10434-014-3639-0","volume":"21","author":"YX Koh","year":"2014","unstructured":"Koh YX, Chok AY, Zheng HL, Tan CS, Goh BKP. Systematic review and meta-analysis comparing the surgical outcomes of invasive intraductal papillary mucinous neoplasms and conventional pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2014;21:2782\u2013800. https:\/\/doi.org\/10.1245\/s10434-014-3639-0.","journal-title":"Ann Surg Oncol."},{"key":"18426_CR25","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.pan.2021.07.009","volume":"21","author":"M Holmberg","year":"2021","unstructured":"Holmberg M, Ghorbani P, Gilg S, et al. Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma. Pancreatology. 2021;21:1371\u20137. https:\/\/doi.org\/10.1016\/j.pan.2021.07.009.","journal-title":"Pancreatology."},{"key":"18426_CR26","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/nejmoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406. https:\/\/doi.org\/10.1056\/nejmoa1809775.","journal-title":"N Engl J Med."},{"key":"18426_CR27","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(16)32409-6.","journal-title":"Lancet."},{"key":"18426_CR28","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(16)30583-9.","journal-title":"Lancet."},{"key":"18426_CR29","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1477-2574.2010.00196.x","volume":"12","author":"O Turrini","year":"2010","unstructured":"Turrini O, Waters JA, Schnelldorfer T, et al. Invasive intraductal papillary mucinous neoplasm: Predictors of survival and role of adjuvant therapy. HPB Oxford. 2010;12:447\u201355. https:\/\/doi.org\/10.1111\/j.1477-2574.2010.00196.x.","journal-title":"HPB Oxford."},{"key":"18426_CR30","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.pan.2020.03.009","volume":"20","author":"C Rodrigues","year":"2020","unstructured":"Rodrigues C, Hank T, Qadan M, et al. Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. Pancreatology. 2020;20:722\u20138. https:\/\/doi.org\/10.1016\/j.pan.2020.03.009.","journal-title":"Pancreatology."},{"key":"18426_CR31","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/jhbp.996","volume":"28","author":"M Choi","year":"2021","unstructured":"Choi M, Chong JU, Hwang HK, et al. Role of postoperative adjuvant therapy in resected invasive intraductal papillary mucinous neoplasm of the pancreas: a multicenter external validation. J Hepatobiliary Pancreat Sci. 2021;28:671\u20139. https:\/\/doi.org\/10.1002\/jhbp.996.","journal-title":"J Hepatobiliary Pancreat Sci."},{"key":"18426_CR32","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1097\/JS9.0000000000000537","volume":"109","author":"M Choi","year":"2023","unstructured":"Choi M, Wang SE, Park JS, et al. Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas: an international multicenter cohort study. Int J Surg. 2023;109:2906\u201313. https:\/\/doi.org\/10.1097\/JS9.0000000000000537.","journal-title":"Int J Surg."},{"key":"18426_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae100","author":"J Lucocq","year":"2024","unstructured":"Lucocq J, Hawkyard J, Haugk B, et al. Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study. Br J Surg. 2024. https:\/\/doi.org\/10.1093\/bjs\/znae100.","journal-title":"Br J Surg."},{"key":"18426_CR34","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ijrobp.2009.02.071","volume":"76","author":"MJ Swartz","year":"2010","unstructured":"Swartz MJ, Hsu CC, Pawlik TM, et al. Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas. Int J Radiat Oncol Biol Phys. 2010;76:839\u201344. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.02.071.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"18426_CR35","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ejso.2012.12.005","volume":"39","author":"S Caponi","year":"2013","unstructured":"Caponi S, Vasile E, Funel N, et al. Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms. Eur J Surg Oncol. 2013;39:396\u2013403. https:\/\/doi.org\/10.1016\/j.ejso.2012.12.005.","journal-title":"Eur J Surg Oncol."},{"issue":"5","key":"18426_CR36","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.hpb.2018.09.013","volume":"21","author":"G Marchegiani","year":"2019","unstructured":"Marchegiani G, Andrianello S, Dal Borgo C, et al. Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data. HPB Oxford. 2019;21(5):596\u2013603. https:\/\/doi.org\/10.1016\/j.hpb.2018.09.013.","journal-title":"HPB Oxford."},{"key":"18426_CR37","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1245\/s10434-020-08916-6","volume":"28","author":"B Mungo","year":"2021","unstructured":"Mungo B, Croce C, Oba A, et al. Controversial role of adjuvant therapy in node-negative invasive intraductal papillary mucinous neoplasm. Ann Surg Oncol. 2021;28:1533\u201342. https:\/\/doi.org\/10.1245\/s10434-020-08916-6.","journal-title":"Ann Surg Oncol."},{"key":"18426_CR38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00268-021-06309-8","volume":"46","author":"E Chong","year":"2022","unstructured":"Chong E, Ratnayake B, Dasari BVM, Loveday BPT, Siriwardena AK, Pandanaboyana S. Adjuvant chemotherapy in the treatment of intraductal papillary mucinous neoplasms of the pancreas: systematic review and meta-analysis. World J Surg. 2022;46:223\u201334. https:\/\/doi.org\/10.1007\/s00268-021-06309-8.","journal-title":"World J Surg."},{"key":"18426_CR39","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.ejso.2022.01.028","volume":"48","author":"DL Hughes","year":"2022","unstructured":"Hughes DL, Hughes I, Silva MA. Determining the role of adjuvant therapy in invasive intraductal papillary mucinous neoplasms; a systematic review and meta-analysis. Eur J Surg Oncol. 2022;48:1567\u201375. https:\/\/doi.org\/10.1016\/j.ejso.2022.01.028.","journal-title":"Eur J Surg Oncol."},{"key":"18426_CR40","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/JCO.23.02313","volume":"42","author":"JR Habib","year":"2024","unstructured":"Habib JR, Kinny-K\u00f6ster B, Javed AA, et al. Impact of adjuvant chemotherapy on resected intraductal papillary mucinous neoplasm-derived pancreatic cancer: results from an international multicenter study. J Clin Oncol. 2024;42:4317\u201326. https:\/\/doi.org\/10.1200\/JCO.23.02313.","journal-title":"J Clin Oncol."},{"key":"18426_CR41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/SLA.0000000000006144","volume":"280","author":"J Lucocq","year":"2024","unstructured":"Lucocq J, Hawkyard J, Robertson FP, et al. Risk of recurrence after surgical resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia (IPMN) with patterns of distribution and treatment: an international, multicenter, observational study (ADENO-IPMN study). Ann Surg. 2024;280:126\u201335. https:\/\/doi.org\/10.1097\/SLA.0000000000006144.","journal-title":"Ann Surg."},{"key":"18426_CR42","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1136\/gut.2010.210567","volume":"60","author":"T Furukawa","year":"2011","unstructured":"Furukawa T, Hatori T, Fujita I, et al. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut. 2011;60:509\u201316. https:\/\/doi.org\/10.1136\/gut.2010.210567.","journal-title":"Gut."},{"key":"18426_CR43","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s11605-022-05428-4","volume":"26","author":"JR Habib","year":"2022","unstructured":"Habib JR, Kinny-K\u00f6ster B, Amini N, et al. Predictors, patterns, and timing of recurrence provide insight into the disease biology of invasive carcinomas arising in association with intraductal papillary mucinous neoplasms. J Gastrointest Surg. 2022;26:2311\u201320. https:\/\/doi.org\/10.1007\/s11605-022-05428-4.","journal-title":"J Gastrointest Surg."},{"key":"18426_CR44","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00535-021-01783-2","volume":"56","author":"T Kobayashi","year":"2021","unstructured":"Kobayashi T, Omori Y, Ono Y, et al. Pathways for the development of multiple epithelial types of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol. 2021;56:581\u201392. https:\/\/doi.org\/10.1007\/s00535-021-01783-2.","journal-title":"J Gastroenterol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18426-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18426-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18426-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:39:46Z","timestamp":1770899986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18426-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["18426"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18426-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Marco Del Chiaro received an industry grant (Haemonetics, Inc) to conduct a multicenter study. Marco Del Chiaro is the co-principal investigator of an international multicenter study sponsored by Boston Scientific. Richard D. Schulick is a co-inventor of a patent licensed to DynamiCure (managed by the University of Colorado) outside the submitted work. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}